Biochemicals and Reagents

OSIP-486823 is a nonsteroidal anti-inflammatory drug that has minimal toxicity and inhibits the activity of cyclooxygenase (COX) and lipoxygenase enzymes. It has been shown to inhibit squamous cell carcinoma in mice, with no effect on normal cells. OSIP-486823 also inhibits the production of PGE2 levels by cancer cells and mitochondrial membrane potential in tumour cells, leading to apoptosis. OSIP-486823 is also an inhibitor of Mcl-1 protein and can be used to treat bowel diseases, such as ulcerative colitis. OSIP-486823 may be used in combination preparations for the treatment of infectious diseases and solid tumours.

ATP-dependent inhibitor of mTOR1/2

2-((1S)-1-[[2-Amino-9H-purin-6-yl]amino]ethyl)-5-methyl-3-(2-methylphenyl)-4(3H)quinazolinone is a synthetic, high purity, potent and selective agonist at the δ subtype of the GABAA receptor. It has been shown to inhibit calcium influx in cells with no effect on chloride influx.

Please enquire for more information about CMP-5 including the price, delivery time and more detailed product information at the technical inquiry form on this page

AVE3085 is a novel drug that inhibits the activity of soluble guanylate cyclase. It has been shown to have a positive effect on cardiac hypertrophy and chronic kidney disease (CKD) by inhibiting the production of reactive oxygen species by pde5 inhibitors and organic nitrates. This drug also has an effect on blood pressure in clinical studies, which may be due to its inhibition of polymerase chain reaction. AVE3085 is currently undergoing phase III clinical trials.

Ro 22-5112 is an investigational pharmaceutical compound primarily characterized as an adrenergic receptor modulator. It is synthetically derived and designed to interact with specific adrenergic receptors within the human body. The mode of action of Ro 22-5112 involves binding to these receptors, leading to the modulation of adrenergic signaling pathways. This interaction can influence various physiological responses such as heart rate, vascular resistance, and neurotransmitter release.

PROTAC CDK9 Degrader-1 is a combination therapy that includes two different types of drugs. One drug inhibits the activity of cyclin-dependent kinases (CDKs). The other drug inhibits the activity of autophagy enzymes. Together, these drugs inhibit the growth of cancer cells and are currently being investigated as a treatment for leukemia and lymphoma in human patients.

ST 045849 is a potent and selective activator of the TRPV1 ion channel, which is predominantly expressed in sensory neurons. ST 045849 has been shown to inhibit the production of inflammatory cytokines and chemokines in vitro as well as in vivo. ST 045849 has also been shown to be an inhibitor of protein interactions with a Kd value of 2 nM for its interaction with the extracellular domain of CXCR4. It has high purity and is available from our catalog.

Erso is a medicinal compound that has been developed to target cancer cells by disrupting the cell cycle and inducing apoptosis. It works by inhibiting the activity of kinases, which are enzymes that play a key role in regulating cell growth and division. Erso has shown promising results in preclinical studies, demonstrating its ability to inhibit tumor growth and induce cancer cell death in both Chinese hamster ovary cells and human cancer cell lines. The protein inhibitor also shows potential for use as a diagnostic tool, as it can be detected in urine samples of patients with certain types of cancer. With its targeted approach to fighting cancer, Erso is poised to become an important tool in the fight against this devastating disease.

Meseclazone is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat inflammation, pain, and stiffness caused by arthritis. Meseclazone is a prodrug that is converted in vivo to mesalazine, its active form. Mesalazine has been shown to have biological properties that are similar to acetylsalicylic acid, including ionotropic gelation. This drug also has the ability to form hydrogen bonds with acidic or basic groups, which helps it act as a cavity filler. Meseclazone also contains a carbonyl group and hydrochloric acid, which can be used for the synthesis of other drugs.